Compare Abeona Therapeutics Inc (ABEO) vs ON Holding AG (ONON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ON Holding AG — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while ON Holding AG trades at $36.4 (market cap $12.21B). The key difference: ON Holding AG is far larger — about 32.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| ABEO | ONON | |
|---|---|---|
Market Cap | $373.32M | $12.21B |
Sector | Health | Technology |
52-Week High | $7.23 | $54.24 |
52-Week Low | $4.17 | $31.88 |
Enterprise Value | $228.22M | $11.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ONON trades at $36.87, up 0.11% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 63.88% gross margin and 15.5% ROE, supported by revenue growth to $3.01B in 2025. Analyst consensus is bullish with a $47.33 price target, though technical indicators suggest near-term resistance.
The outlook remains positive given consistent earnings outperformance and raised profit guidance, but risks include tariff concerns and competitive pressures. Upside potential exists if the company maintains its innovation-led growth, particularly in Asia-Pacific markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
